Acquipharma
VC Fund
Acquipharma is a VC fund focused on Finance and Medical. Acquipharma is headed by Oppel Greeff, a medical doctor and a former executive with publicly traded Quintiles Transnational Corp.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Acquipharma invests in
Stages Acquipharma invests in
Countries Acquipharma invests in
Round sizes
Round size
- Series B
- $7.5M–$18M
Investment Focus
Industry
- Finance 1 (20%)
- Medical 1 (20%)
- Health Care 1 (20%)
- Life Science 1 (20%)
- Biotechnology 1 (20%)
Stage
- Series A 1 (20%)
- Series B 1 (20%)
- Funding Round 1 (20%)
- Venture - Series Unknown 1 (20%)
Country
- India 1 (20%)
- United States 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Burl Concepts is a San Diego-based medical device start-up that manufactures portable ultrasound device to detect strokes in the field. It was founded in order to bring a portable and affordable pre-hospital stroke detection solution to millions of at-risk people worldwide.Fueled by an interdisciplinary exchange of ideas between the naturalsciences and engineering disciplines, the company seeks to bring academic institutions and industrial partners together to meet today’s challenges in global medical care. The first product from BURL Concepts is the SONAS portable, battery-powered ultrasound device designed for the non-invasive, transcranial diagnosis of major strokes.Founded in 2013, Burl Concepts is based on the research of Thilo Hoelscher, a neurologist who previously served as a professor at UC San Diego, where he founded the UCSD Brain Ultrasound Research Laboratory. | $4.5M / Sep 02, 2025 | ||
| BUGWORKS is a drug discovery company that aims to discover novel pharmaceutical assets for combating Antimicrobial Resistance (AMR). The company was founded in 2014 and is based in Bangalore, India. | $18M / Series B / Feb 09, 2022 | ||
| BUGWORKS is a drug discovery company that aims to discover novel pharmaceutical assets for combating Antimicrobial Resistance (AMR). The company was founded in 2014 and is based in Bangalore, India. | $7.5M / Series B / Apr 22, 2020 | ||
| BUGWORKS is a drug discovery company that aims to discover novel pharmaceutical assets for combating Antimicrobial Resistance (AMR). The company was founded in 2014 and is based in Bangalore, India. | $9M / Series A / Aug 13, 2018 | ||
| Burl Concepts is a San Diego-based medical device start-up that manufactures portable ultrasound device to detect strokes in the field. It was founded in order to bring a portable and affordable pre-hospital stroke detection solution to millions of at-risk people worldwide.Fueled by an interdisciplinary exchange of ideas between the naturalsciences and engineering disciplines, the company seeks to bring academic institutions and industrial partners together to meet today’s challenges in global medical care. The first product from BURL Concepts is the SONAS portable, battery-powered ultrasound device designed for the non-invasive, transcranial diagnosis of major strokes.Founded in 2013, Burl Concepts is based on the research of Thilo Hoelscher, a neurologist who previously served as a professor at UC San Diego, where he founded the UCSD Brain Ultrasound Research Laboratory. | $3M / Venture - Series Unknown / Oct 04, 2016 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Acquipharma invest in?
Acquipharma invests primarily in Finance, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Acquipharma's check size?
Acquipharma typically joins rounds of $7.5M–$18M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Acquipharma participates in.
When did Acquipharma last invest?
The most recent investment recorded for Acquipharma closed in Sep 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
